CD4 and primary cutaneous T-cell non-Hodgkin lymphoma: Thus, we also developed an autologous mCAR-Vβ2 T cell model by using purified CD8+ T cells from a Vβ2+ CTCL patient as the source of mCAR-Vβ2 T cells to target the patient’s (CD4+) Vβ2+ CTCL cells.